Litcius/Paper detail

Distinct molecular patterns of TDP-43 pathology in Alzheimer’s disease: relationship with clinical phenotypes

Sandra O. Tomé, Rik Vandenberghe, Simona Ospitalieri, Evelien Van Schoor, Thomas Tousseyn, Markus Otto, Christine A. F. Von Arnim, Dietmar Rudolf Thal

2020Acta Neuropathologica Communications109 citationsDOIOpen Access PDF

Abstract

Abstract The co-existence of multiple pathologies and proteins is a common feature in the brains of cognitively impaired elderly individuals. Transactive response DNA-binding protein (TDP-43) has been discovered to accumulate in limbic brain regions of a portion of late-onset Alzheimer’s disease (AD) patients, in addition to amyloid-β and τ protein. However, it is not yet known whether the TDP-43 species in the AD brain differ in their composition, when compared among different AD cases and to frontotemporal lobar degeneration cases with TDP-43 inclusions (FTLD-TDP). Furthermore, it is not known whether TDP-43 pathology in AD is related to symptoms of the frontotemporal dementia (FTD) spectrum. In this study, we investigated the molecular pattern of TDP-43 lesions with five different antibodies against different phosphorylated (pTDP-43) and non-phosphorylated TDP-43 epitopes. We analyzed a cohort of 97 autopsy cases, including brains from 20 non-demented individuals, 16 cognitively normal pathologically-defined preclinical AD (p-preAD), 51 neuropathologically-confirmed AD cases and 10 FTLD-TDP cases as positive controls. We observed distinct neuropathological patterns of TDP-43 among AD cases. In 11 neuropathologically-confirmed AD cases we found dystrophic neurites (DNs), neuronal cytoplasmic inclusions (NCIs) and/or neurofibrillary tangle (NFT)-like lesions not only positive for pTDP-43 409/410 , but also for pTDP-43 phosphorylated at serines 403/404 (pTDP-43 403/404 ) and non-phosphorylated, full-length TDP-43, as seen with antibodies against C-terminal TDP-43 and N-terminal TDP-43. These cases were referred to as AD TDP + FL because full-length TDP-43 was presumably present in the aggregates. FTLD-TDP cases showed a similar molecular TDP-43 pattern. A second pattern, which was not seen in FTLD-TDP, was observed in most of p-preAD, as well as 30 neuropathologically-confirmed AD cases, which mainly exhibited NFTs and NCIs stained with antibodies against TDP-43 phosphorylated at serines 409/410 (pTDP-43 409 , pTDP-43 409/410 ). Because only phosphorylated C-terminal species of TDP-43 could be detected in the lesions we designated these AD cases as AD TDP + CTF . Ten AD cases did not contain any TDP-43 pathology and were referred to as AD TDP- . The different TDP-43 patterns were associated with clinically typical AD symptoms in 80% of AD TDP + CTF cases, 63,6% of AD TDP + FL and 100% of the AD TDP- cases. On the other hand, clinical symptoms characteristic for FTD were observed in 36,4% of AD TDP + FL , in 16,6% of the AD TDP + CTF , and in none of the AD TDP- cases. Our findings provide evidence that TDP-43 aggregates occurring in AD cases vary in their composition, suggesting the distinction of different molecular patterns of TDP-43 pathology ranging from AD TDP- to AD TDP + CTF and AD TDP + FL with possible impact on their clinical picture, i.e. a higher chance for FTD-like symptoms in AD TDP + FL cases.

Topics & Concepts

Frontotemporal lobar degenerationPathologyDementiaFrontotemporal dementiaAlzheimer's diseaseBiologyDiseaseMedicineAlzheimer's disease research and treatmentsAmyotrophic Lateral Sclerosis ResearchPrion Diseases and Protein Misfolding
Distinct molecular patterns of TDP-43 pathology in Alzheimer’s disease: relationship with clinical phenotypes | Litcius